Osiris Therapeutics

Last update: December 23, 2019

United States (USA) Its 10 main executives

Recent executive movements at Smith & Nephew

Ian Melling who is Senior Vice President, Group Finance, will become Interim Chief Financial Officer on May 1, 2020  (news posted on March 5 2020).
Rick Medlock will join the company as Non-Executive Director on Apr. 9, 2020  (news posted on March 5 2020).
Graham Baker, Chief Financial Officer and Executive Director, will leave the company on Apr. 30, 2020  (news posted on March 5 2020).

Click here to view some more movements at Smith & Nephew

Create an alert
to follow the executive moves at Osiris Therapeutics.

Latest M&A news in Biotechnology.

Thermo Fisher Scientific has announced the acquisition of Qiagen (posted on Mar 5, 2020).
Sanofi has acquired Synthorx (posted on Jan 23, 2020).
Sanofi has acquired Synthorx (posted on Jan 23, 2020).

Latest news about Osiris Therapeutics

Osiris Therapeutics on Wikipedia, Google News & Yahoo Finance

Osiris Therapeutics on LinkedIn, Twitter & YouTube

Osiris Therapeutics has 1,342 competitors including Biogen (United States (USA)), Genentech (United States (USA)) and Eurofins (France). Osiris Therapeutics is owned by Smith & Nephew.

The most constantly updated executive directory.



Learn about your clients' org charts. Understand their industries and their competitors.



View the executives' biographies. Contact the executives through our email platform.



Select key words to follow your clients. Receive alerts when executive movements happen.


Track your clients

File your clients in folders. Add private notes. Download our data in Excel on your PC.